AU2020202887B2 - Methods of treating heart failure with reduced ejection fraction with dapagliflozin - Google Patents

Methods of treating heart failure with reduced ejection fraction with dapagliflozin Download PDF

Info

Publication number
AU2020202887B2
AU2020202887B2 AU2020202887A AU2020202887A AU2020202887B2 AU 2020202887 B2 AU2020202887 B2 AU 2020202887B2 AU 2020202887 A AU2020202887 A AU 2020202887A AU 2020202887 A AU2020202887 A AU 2020202887A AU 2020202887 B2 AU2020202887 B2 AU 2020202887B2
Authority
AU
Australia
Prior art keywords
patient
heart failure
dapagliflozin
care
standard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020202887A
Other languages
English (en)
Other versions
AU2020202887A1 (en
Inventor
Anna Maria LANGKILDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2020202887A1 publication Critical patent/AU2020202887A1/en
Application granted granted Critical
Publication of AU2020202887B2 publication Critical patent/AU2020202887B2/en
Priority to AU2021215150A priority Critical patent/AU2021215150B2/en
Priority to AU2023210548A priority patent/AU2023210548B2/en
Priority to AU2025204486A priority patent/AU2025204486A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
AU2020202887A 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin Active AU2020202887B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021215150A AU2021215150B2 (en) 2019-08-30 2021-08-10 Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2023210548A AU2023210548B2 (en) 2019-08-30 2023-07-31 Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2025204486A AU2025204486A1 (en) 2019-08-30 2025-06-17 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962893849P 2019-08-30 2019-08-30
US62/893,849 2019-08-30
US201962930673P 2019-11-05 2019-11-05
US62/930,673 2019-11-05
US201962946625P 2019-12-11 2019-12-11
US62/946,625 2019-12-11
US202062960756P 2020-01-14 2020-01-14
US62/960,756 2020-01-14
US202062969181P 2020-02-03 2020-02-03
US62/969,181 2020-02-03
US202062985407P 2020-03-05 2020-03-05
US62/985,407 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021215150A Division AU2021215150B2 (en) 2019-08-30 2021-08-10 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Publications (2)

Publication Number Publication Date
AU2020202887A1 AU2020202887A1 (en) 2021-03-18
AU2020202887B2 true AU2020202887B2 (en) 2021-05-20

Family

ID=69784449

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2020202887A Active AU2020202887B2 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2021215150A Active AU2021215150B2 (en) 2019-08-30 2021-08-10 Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2023210548A Active AU2023210548B2 (en) 2019-08-30 2023-07-31 Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2025204486A Pending AU2025204486A1 (en) 2019-08-30 2025-06-17 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021215150A Active AU2021215150B2 (en) 2019-08-30 2021-08-10 Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2023210548A Active AU2023210548B2 (en) 2019-08-30 2023-07-31 Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2025204486A Pending AU2025204486A1 (en) 2019-08-30 2025-06-17 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Country Status (18)

Country Link
US (3) US10973836B2 (https=)
EP (1) EP4021507A1 (https=)
JP (4) JP7756487B2 (https=)
KR (3) KR102359799B1 (https=)
CN (1) CN112752582A (https=)
AU (4) AU2020202887B2 (https=)
BR (1) BR112020008705A2 (https=)
CA (1) CA3079175A1 (https=)
CL (1) CL2020001335A1 (https=)
CR (1) CR20200224A (https=)
IL (1) IL274020A (https=)
JO (1) JOP20200098A1 (https=)
MX (2) MX2020005388A (https=)
PE (1) PE20211267A1 (https=)
PH (1) PH12020551141A1 (https=)
SG (1) SG11202003971RA (https=)
TW (3) TWI786398B (https=)
WO (1) WO2021037400A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
EP4138826A1 (en) * 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US20240100013A1 (en) * 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023175573A1 (en) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
US20250205317A1 (en) * 2022-03-28 2025-06-26 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
CR20250112A (es) * 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
EP4640213A1 (en) * 2022-12-20 2025-10-29 THPharm Corp. Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266152A1 (en) * 2016-03-16 2017-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020016335A1 (en) * 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2007093610A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
JP2011506363A (ja) 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全の処置および／または予防用のオキサゾリジノン類
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX367404B (es) 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
JP2017528499A (ja) * 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
EP3508222A4 (en) * 2016-08-30 2020-04-29 Niigata University MEDICINES FOR REMOVING AGED CELLS
WO2018142422A1 (en) 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
TW202220672A (zh) * 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266152A1 (en) * 2016-03-16 2017-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020016335A1 (en) * 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCMURRAY, J.J.V., et al., European Journal of Heart Failure (2019) vol. 21, pages 665-675 *
TANAKA, A., et al., SSRN ELECTRONIC JOURNAL (2019), DOI: 10.2139/ssrn.3343659 (EPub 2 March 2019) *

Also Published As

Publication number Publication date
US20210260083A1 (en) 2021-08-26
TW202335668A (zh) 2023-09-16
JP2023025207A (ja) 2023-02-21
JOP20200098A1 (ar) 2021-02-28
TW202108134A (zh) 2021-03-01
CL2020001335A1 (es) 2021-07-09
US20240216404A1 (en) 2024-07-04
TWI786398B (zh) 2022-12-11
IL274020A (en) 2021-03-01
BR112020008705A2 (pt) 2022-03-22
WO2021037400A1 (en) 2021-03-04
KR102359799B1 (ko) 2022-02-09
KR20210027229A (ko) 2021-03-10
AU2021215150A1 (en) 2021-09-02
CN112752582A (zh) 2021-05-04
PE20211267A1 (es) 2021-07-19
CA3079175A1 (en) 2021-02-28
SG11202003971RA (en) 2021-04-29
KR20220044234A (ko) 2022-04-07
TWI859649B (zh) 2024-10-21
AU2023210548A1 (en) 2023-08-17
US20210060043A1 (en) 2021-03-04
AU2020202887A1 (en) 2021-03-18
US11903955B2 (en) 2024-02-20
AU2021215150B2 (en) 2023-05-04
MX2020005388A (es) 2022-10-25
AU2025204486A1 (en) 2025-07-03
JP7494277B2 (ja) 2024-06-03
JP2025108488A (ja) 2025-07-23
AU2023210548B2 (en) 2025-04-17
CR20200224A (es) 2021-05-26
JP2022530575A (ja) 2022-06-30
PH12020551141A1 (en) 2021-05-31
US10973836B2 (en) 2021-04-13
EP4021507A1 (en) 2022-07-06
JP7756487B2 (ja) 2025-10-20
TW202504616A (zh) 2025-02-01
MX2022008018A (es) 2022-07-27
KR20240166611A (ko) 2024-11-26
JP2024119842A (ja) 2024-09-03

Similar Documents

Publication Publication Date Title
AU2020202887B2 (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
Seferovic et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
Hunt et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation
Rao et al. Practical patient care considerations with use of vericiguat after worsening heart failure events
Oh et al. Sodium-glucose co-transporter 2 inhibitors: a new path for heart failure treatment
CN112336713B (zh) 达格列净在制备治疗射血分数降低的心力衰竭的药物中的用途
EA042257B1 (ru) Способы лечения сердечной недостаточности со сниженной фракцией выброса с помощью дапаглифлозина
HK40046452A (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
HK40117723A (zh) 利用达格列净治疗射血分数降低的心力衰竭的方法
BR122025016233A2 (pt) Usos de composições farmacêuticas que compreendem um inibidor do sglt2
HK40046452B (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
HK40051086A (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
WO2025190858A1 (en) Aldosterone synthase inhibitor for treating heart failure
SINDONE et al. How to optimise therapy
Seferovic Clinical practice update on heart failure 2019 Seferovic, Petar M.; Ponikowski, Piotr; Anker, Stefan D.; Bauersachs, Johann; Chioncel, Ovidiu; Cleland, John GF; de Boer, Rudolf A.; Drexel, Heinz; Ben Gal, Tuvia; Hill, Loreena
Lyon et al. The year in cardiology: heart failure The year in cardiology 2019
Seferovic Seferovic, PM et al.(2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 21 (10), pp. 1169-1186.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)